Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for psoriatic arthritis-pyoderma gangrenosum-acne-hidradenitis suppurativa syndrome.
6 publications have been identified in PubMed for psoriatic arthritis-pyoderma gangrenosum-acne-hidradenitis suppurativa syndrome. Research spans Case Report / Case Series (100%).
Henriques Afonso C (2026). [PMID: 41732717](https://pubmed.ncbi.nlm.nih.gov/41732717/). *Interv Pain Med*. [Case Report / Case Series]
Tikka M (2025). [PMID: 40824161](https://pubmed.ncbi.nlm.nih.gov/40824161/). *Acta Derm Venereol*. [Case Report / Case Series]
Takei I (2025). [PMID: 40612847](https://pubmed.ncbi.nlm.nih.gov/40612847/). *Cureus*. [Case Report / Case Series]
Patel J (2025). [PMID: 41499625](https://pubmed.ncbi.nlm.nih.gov/41499625/). *WMJ*. [Case Report / Case Series]
Shevtsova IN (2025). [PMID: 40309341](https://pubmed.ncbi.nlm.nih.gov/40309341/). *Case Rep Rheumatol*. [Case Report / Case Series]
Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 5:42 PM UTC
European rare disease database
AI-curated news mentioning psoriatic arthritis-pyoderma gangrenosum-acne-hidradenitis suppurativa syndrome
Updated Feb 4, 2026
Eli Lilly reported $19.3 billion in revenue for Q4 and is expanding its GLP-1 franchise into immunology and inflammation. Ongoing trials target asthma, psoriatic arthritis, Crohn's disease, and ulcerative colitis.